Patient number | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
Age at first visit | 35 | 30 | 49 | 36 | 48 | 49 | 36 | 53 | 49 |
Gender | Male | Male | Female | Male | Male | Male | Male | Female | Female |
Ethnicity | Black | Hispanic | Black | Black | Black | Black | Hispanic | Black | Black |
Rheumatic disease | Enteropathic arthritis (Peripheral SpA) | PsA | Ankylosing spondylitis (AS) | PsA | Seronegative RA | Non-radiographic axial SpA | Peripheral SpA | Non -radiographic axial SpA | Peripheral SpA |
Anti-TNF agent usage | Not taking | Currently taking | Not taking | Currently taking | Switched to upadacitinib | Not taking | Currently taking | Switched to secukinumab | Currently taking |
Taking cART | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Baseline CD4 (cells/μL) | 583 | 185 | 614 | 562 | 599 | 440 | 1300 | 827 | 2618 |
Baseline viral (copies/mL) | 1788 | 535 | Undetectable | 4500 | 384 | Undetectable | Undetectable | Undetectable | Undetectable |
Duration of anti-TNF treatment | 2006–2010 | 2010–present | 2013–2013 | 2010–present | 2013–2016, 2020–present | 2014–2014 | 2019–present | 2020–present | 2020–present |
Still followed | Last seen 2015 | Current patient | Current patient | Current patient | Current patient | Current patient | Current patient | Current patient | Current patient |
Lowest CD4 on anti-TNF treatment (cells/μL) | 403 | 303 | 677 | 217 | 599 | 389 | 1144 | 815 | 1416 |
Highest viral load on anti-TNF treatment (copies/mL) | 35 200 | 43 700 | Undetectable | 45 500 | 384 | Undetectable | Undetectable | 8390 | Undetectable |
Most recent CD4 count (cells/μL) | 583 | 771 | 1040 | 365 | 266 | 592 | 1757 | 3886 | 2402 |
Most recent HIV viral load | 164 000 | 38 | Undetectable | 14 000 | Undetectable | Undetectable | Undetectable | Undetectable | Undetectable |
Anti-TNF agent used | Adalimumab | Etanercept, adalimumab | Etanercept | Adalimumab, etanercept | Etanercept, | Etanercept | Adalimumab | Adalimumab, | Adalimumab |
Other biologic/anti-JAK agents used | None | None | None | None | Upadacitinib | None | None | Secukinumab | None |
Clinical response to therapy | Partial | Etanercept-transient, adalimumab-good | Good | Adalimumab-transient, etanercept-good | Excellent | Transient | Excellent | Good | Good |
Complications of biological treatment | Rising viral load | None | None | None | None | None | None | None | None |
cART, combined antiretroviral therapy; JAK, Janus kinase; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis; TNF, tumour necrosis factor.